What one share of Inhibrx Biosciences holds
We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms we believe to be superior to current approaches and applicable to a range of challenging, validated targets with high potential.
Inhibrx Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$8.88 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$8.47 |
| Cash and investments | $9.07 |
| Debt | $11.98 |
| Book value | −$3.60 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.15 | −$20.48 | $0.39 | −$16.80 | — | — |
| 2024 | $0.01 | $112.62 | $0.17 | −$13.15 | — | $9.23 |
| 2025 | $0.08 | −$9.04 | $0.00 | −$8.38 | — | $0.55 |
Common questions about Inhibrx Biosciences
How much does one share of Inhibrx Biosciences earn?
Over the last 12 months, Inhibrx Biosciences lost $8.88 for each share.
Does Inhibrx Biosciences pay a dividend?
Inhibrx Biosciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Inhibrx Biosciences’s book value per share?
Inhibrx Biosciences’s book value is negative (−$3.60 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Inhibrx Biosciences have?
Each share of Inhibrx Biosciences has $9.07 of cash and investments and $11.98 of debt, as of June 30, 2026.
What is Inhibrx Biosciences’s free cash flow per share?
−$8.47 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.